CD81 and plasma cell myeloma: It has been reported that 1q21 gain is closely associated with a poor prognosis.22, 23 In 2016, the International Myeloma Working Group defined 1q21 gain as a high‐risk genetic factor.24 The findings that led to that definition may help explain the poor prognosis of the CD81(+) patients.